Suchergebnisse - "Kim, Edward"

PubPharm (33)

1

Radioembolization plus Immune Checkpoint Inhibitor Therapy Compared with Radioembolization plus Tyrosine Kinase Inhibitor Therapy for the Treatment of Hepatocellular Carcinoma

enthalten in: Journal of vascular and interventional radiology : JVIR | 2024

von Garcia-Reyes, K. | Gottlieb, R. | Menon, K. | +13

2

Response to : Efficacy of Brigatinib After Progression on Alectinib or Ceritinib: Does One Drug Work in a Pretreated Heterogeneous ALK-Positive NSCLC Population?

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2023

von Ou, S. | Kim, E.

CommentOn: J Thorac Oncol. 2022 Dec;17(12):1404-1414. - PMID 36096442

3

Efficacy of Brigatinib in Patients With Advanced ALK-Positive NSCLC Who Progressed on Alectinib or Ceritinib : ALK in Lung Cancer Trial of brigAtinib-2 (ALTA-2)

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2022

von Ou, S. | Nishio, M. | Ahn, M. | +20

CommentIn: J Thorac Oncol. 2023 Mar;18(3):e28-e29. - PMID 36842817

4

Rationale and design of ON-TRK : a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib

enthalten in: BMC cancer | 2022

von Yang, J. | Brose, M. | Castro, G. | +13

5

Comparing EGFR tyrosine kinase inhibitor treatments in EGFR-mutated non-small cell lung cancer across Asian and non-Asian patients : a plain language summary

enthalten in: Future oncology (London, England) | 2022

von Kim, E.

CommentOn: Future Oncol. 2021 Jun;17(18):2395-2408. - PMID 33855865

6

Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors

enthalten in: Cancer chemotherapy and pharmacology | 2021

von Semrad, T. | Kim, E. | Gong, I. | +6

7

EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer : outcomes in Asian populations

enthalten in: Future oncology (London, England) | 2021

von Kim, E. | Melosky, B. | Park, K. | +2

CommentIn: Future Oncol. 2022 Feb;18(4):417-424. - PMID 34918542

8

Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

enthalten in: Investigational new drugs | 2021

von Kenney, C. | Kunst, T. | Webb, S. | +6

9

ALTA-2 : Phase II study of brigatinib in patients with ALK-positive, advanced non-small-cell lung cancer who progressed on alectinib or ceritinib

enthalten in: Future oncology (London, England) | 2021

von Kim, E. | Barlesi, F. | Mok, T. | +4

10

Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations : A Database of 693 Cases

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2020

von Yang, J. | Schuler, M. | Popat, S. | +5

CommentIn: J Thorac Oncol. 2020 May;15(5):681-685. - PMID 32340673